Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of Effect of LY3556050 on Metformin in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3556050
Drug: Metformin
Drug: Iohexol

First Posted Date: 2022-11-14

Last Posted Date: 2023-01-18

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 18

Registration Number: NCT05615467

Locations: 🇺🇸
PRA International, Salt Lake City, Utah, United States

A Study of LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3

Phase 1

Recruiting

Conditions: Neoplasm Metastasis
Urinary Bladder Neoplasms
Ureteral Neoplasms

Interventions: Drug: LOXO-435
Drug: Pembrolizumab

First Posted Date: 2022-11-14

Last Posted Date: 2024-11-18

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 180

Registration Number: NCT05614739

Locations: 🇦🇺
Calvary Mater Newcastle, Waratah, New South Wales, Australia
🇫🇷
Gustave Roussy, Villejuif Cedex, France
🇮🇹
UOC Fase I - Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore, Roma, Italy

and more 54 locations

A Relative Bioavailability Study of LY3209590 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3209590 (SC)
Drug: LY3209590 (IV)

First Posted Date: 2022-11-14

Last Posted Date: 2024-06-12

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 168

Registration Number: NCT05615532

Locations: 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore

Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

Phase 2

Active, not recruiting

Conditions: Obesity
Overweight or Obesity
Obese

Interventions: Biological: Bimagrumab
Drug: Semaglutide
Other: Bimagrumab Placebo

First Posted Date: 2022-11-14

Last Posted Date: 2024-12-18

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 507

Registration Number: NCT05616013

Locations: 🇺🇸
Pinnacle Research Group, LLC, Anniston, Alabama, United States
🇺🇸
Cullman Clinical Trials, Cullman, Alabama, United States
🇺🇸
Indago Research & Health Center, Inc, Hialeah, Florida, United States

and more 23 locations

A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function

Phase 1

Completed

Conditions: Healthy
Renal Insufficiency

Interventions: Drug: LY3437943

First Posted Date: 2022-11-10

Last Posted Date: 2023-10-02

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 29

Registration Number: NCT05611957

Locations: 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸
Nucleus Networks, Saint Paul, Minnesota, United States

and more 1 locations

A Study of LY3875383 in Healthy Participants and Participants With Hypertriglyceridemia

Phase 1

Completed

Conditions: Hypertriglyceridemia

Interventions: Drug: LY3875383
Drug: Placebo

First Posted Date: 2022-11-08

Last Posted Date: 2024-03-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 41

Registration Number: NCT05609825

Locations: 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore

A Drug Interaction Study of LY3871801 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3871801
Drug: Methotrexate
Drug: Warfarin
Drug: Dextromethorphan
Drug: Midazolam
Drug: Repaglinide

First Posted Date: 2022-11-02

Last Posted Date: 2023-04-18

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 39

Registration Number: NCT05602675

Locations: 🇺🇸
Covance Dallas, Dallas, Texas, United States

A Study of LY3209590 in Chinese Participants With Type 2 Diabetes Mellitus

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: LY3209590
Drug: Insulin Glargine

First Posted Date: 2022-10-27

Last Posted Date: 2024-01-02

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 31

Registration Number: NCT05596747

Locations: 🇨🇳
Tianjin Medical University General Hospital, Tianjin, Tianjin, China

A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

Phase 2

Active, not recruiting

Conditions: Heart Failure
Heart Failure With Preserved Ejection Fraction

Interventions: Drug: Placebo
Drug: LY3540378

First Posted Date: 2022-10-24

Last Posted Date: 2024-12-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 456

Registration Number: NCT05592275

Locations: 🇺🇸
Pima Heart, Tucson, Arizona, United States
🇺🇸
Valley Clinical Trials, Inc., Northridge, California, United States
🇺🇸
Pasadena Clinical Research, Pasadena, California, United States

and more 133 locations

A Study of LY3457263 in Obese Participants

Phase 1

Completed

Conditions: Overweight
Obesity

Interventions: Drug: LY3457263
Drug: Tirzepatide
Drug: Placebo

First Posted Date: 2022-10-17

Last Posted Date: 2023-07-18

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 38

Registration Number: NCT05582096

Locations: 🇺🇸
LabCorp CRU, Inc., Daytona Beach, Florida, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy